http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Press+Releases/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html <p align="justify">CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “<strong>IR Agreement</strong>”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Termination+and+Postponement+of+Investor+Relations+Program/26992920.html Fri, 28 Aug 2026 07:00:00 -0400 A.14191503 A.14440365 A.36078215 ANU O.02555813 O.07556890 O.28734418 O.36953541 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html <p align="justify">CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.</p> <p align="justify">Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman of the board during the past several years. Anthony’s contribution to http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html Fri, 31 Jul 2026 17:00:00 -0400 ANU O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html <p align="justify">CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.</p> <p align="justify">Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman of the board during the past several years. Anthony’s contribution to http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html Fri, 31 Jul 2026 17:00:00 -0400 ANU O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html <p align="justify">CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.</p> <p align="justify">Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman of the board during the past several years. Anthony’s contribution to http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html Fri, 31 Jul 2026 17:00:00 -0400 ANU O.28734418 XRTX XRTX http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html <p align="justify">CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.</p> <p align="justify">Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman of the board during the past several years. Anthony’s contribution to http://www.streetinsider.com/Press+Releases/XORTX+Announces+Director+Resignation/26851518.html Fri, 31 Jul 2026 17:00:00 -0400 ANU O.28734418 XRTX XRTX http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Director+Resignation/26851518.html <p align="justify">CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (&quot;<strong>XORTX</strong>&quot; or the “<strong>Company</strong>”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.</p> <p align="justify">Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman of the board during the past several years. Anthony’s contribution to http://www.streetinsider.com/Globe+Newswire/XORTX+Announces+Director+Resignation/26851518.html Fri, 31 Jul 2026 17:00:00 -0400 ANU O.28734418 XRTX XRTX